Patents by Inventor M. Michael Wolfe

M. Michael Wolfe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260345733
    Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
    Type: Application
    Filed: November 26, 2025
    Publication date: November 5, 2026
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Patent number: 12508299
    Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: December 30, 2025
    Assignee: METROHEALTH VENTURES LLC
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20250304675
    Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.
    Type: Application
    Filed: October 16, 2024
    Publication date: October 2, 2025
    Inventor: M. Michael Wolfe
  • Publication number: 20250109196
    Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.
    Type: Application
    Filed: October 16, 2024
    Publication date: April 3, 2025
    Inventor: M. Michael Wolfe
  • Publication number: 20230020626
    Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
    Type: Application
    Filed: June 24, 2022
    Publication date: January 19, 2023
    Inventors: M. Michael WOLFE, Michael O. BOYLAN
  • Patent number: 11400135
    Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 2, 2022
    Assignee: MHS CARE-INNOVATION LLC
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20210347883
    Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Inventor: M. Michael Wolfe
  • Patent number: 11066467
    Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: July 20, 2021
    Assignee: MHS CARE-INNOVATION LLC
    Inventor: M. Michael Wolfe
  • Publication number: 20200155649
    Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
    Type: Application
    Filed: February 4, 2020
    Publication date: May 21, 2020
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Patent number: 10548951
    Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 4, 2020
    Assignee: MHS CARE-INNOVATION LLC
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Patent number: 10538586
    Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: January 21, 2020
    Assignee: MHS CARE-INNOVATION LLC
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20190322738
    Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 24, 2019
    Inventor: M. Michael Wolfe
  • Patent number: 10196441
    Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: February 5, 2019
    Assignee: THE METROHEALTH SYSTEM
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20180140630
    Abstract: A combination of an antacid, alginate, and a histamine H2-receptor antagonist, and methods of using the same for providing fast and lasting relief of symptoms of episodic heartburn are provided.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 24, 2018
    Inventors: M. Michael Wolfe, Steven B. Landau, Abhijeet Waghray, Nisheet Waghray
  • Publication number: 20180028618
    Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
    Type: Application
    Filed: September 25, 2017
    Publication date: February 1, 2018
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20180030133
    Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
    Type: Application
    Filed: September 25, 2017
    Publication date: February 1, 2018
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Patent number: 9771422
    Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: September 26, 2017
    Assignee: MHS CARE-INNOVATION LLC
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20170044254
    Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20150166657
    Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 18, 2015
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Publication number: 20090291883
    Abstract: The present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of a NSAID in combination with an effective amount of an immunosuppressant agent. In particular, the present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of COX-2 inhibitor in combination with an effective amount of an immunosuppressant agent.
    Type: Application
    Filed: July 16, 2007
    Publication date: November 26, 2009
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: M. Michael Wolfe, Min Yao